By the WoundSource Editors
Reykjavik, Iceland — May 23, 2017 — The Icelandic Growth Consortium today named Kerecis the country’s fastest growing startup. Kerecis is the creator, manufacturer and patent holder of revolutionary fish-skin-based therapeutic products that speed up the healing process of chronic human wounds and repairs tissue damage.
The award acknowledges that Kerecis showed the fastest revenue growth year-to-year compared to the other nominated startups. It confirms that Kerecis spends more than 20 percent of its revenue on research and development activities, and that its founders still retain a significant stake in the company.
“This award recognizes the financial milestones we have reached in the past year, as the efficacy of our fish-skin-based products becomes more well-known, and as the products themselves become more available worldwide,” said G. Fertram Sigurjonsson, founder and CEO of Kerecis.
The company’s products are now available in the United States, Iceland, Germany, and several other European and Asian countries. Specifically, the product has been approved by the FDA and European regulatory authorities and is eligible for reimbursement by Medicare in the U.S.
Kerecis™ Omega3 is intact fish skin that is rich in naturally occurring Omega3 polyunsaturated fatty acids. When grafted onto damaged human tissue such as a diabetic wound, the acellular material recruits the body’s cells from the wound perimeter. The cells are then incorporated into the fish skin, which is ultimately converted into functional, living tissue. Research has shown that the patented material helps heal chronic and hard-to-heal wounds, including diabetic, venous, foot and pressure ulcers.The fish skin used in Kerecis’s products derives from wild and sustainable fish stock caught in pristine Icelandic waters and processed with 100% renewable energy in a township at the polar circle.
About the Icelandic Growth Consortium
The Icelandic Growth Consortium consists of the Federation of Icelandic Industries, Iceland Startups, University of Reykjavik and the Icelandic Research Institute.
Kerecis develops regenerative technologies based on fish skin and Omega3 polyunsaturated fatty acids. The technology is patented in the United States and multiple other countries. The initial Kerecis product, Kerecis Omega3 Wound, has been approved by the FDA and European regulatory authorities for wound healing. The Kerecis technology has also been approved for use as a surgical buttress (Kerecis Omega3 SecureMesh) and as a treatment for burn wounds (Kerecis Omega3 Burn). Production takes place in the Kerecis manufacturing facilities in Iceland. For more information, visit www.kerecis.com. Distributor inquiries are welcome.
The views and opinions expressed in this blog are solely those of the author, and do not represent the views of WoundSource, Kestrel Health Information, Inc., its affiliates, or subsidiary companies.